文献速递乳腺癌

小乳腺癌且腋窝淋巴结超声阴性患者的前哨淋巴结活检与不做腋窝手术对比:SOUND随机临床试验

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

SOUND试验为前瞻性非劣效3期随机临床试验,纳入1463例肿瘤≤2 cm且术前腋窝超声阴性的乳腺癌女性,1:1随机接受前哨淋巴结活检(SLNB)或不做腋窝手术。意向治疗分析1405例,5年远处无病生存率SLNB组97.7% vs 不做腋窝手术组98.0%(log-rank P=.67;HR 0.84;90%CI 0.45-1.54;非劣效P=.02),不做腋窝手术非劣效于SLNB。

要点

  • 肿瘤≤2 cm且腋窝超声阴性的乳腺癌患者,不做腋窝手术在5年远处无病生存上非劣效于SLNB。
  • SLNB组5年远处无病生存率97.7%,不做腋窝手术组98.0%(HR 0.84;90%CI 0.45-1.54)。
  • 作者认为,当缺乏病理信息不影响术后治疗计划时,此类患者可安全免除任何腋窝手术。

核心结论

  • 在肿瘤≤2 cm且术前腋窝淋巴结超声阴性的乳腺癌患者中,不做腋窝手术在5年远处无病生存方面非劣效于前哨淋巴结活检。
  • 作者认为,当缺乏病理信息不影响术后治疗计划时,具有这些特征的患者可安全免除任何腋窝手术。

研究设计与样本

  • SOUND(Sentinel Node vs Observation After Axillary Ultra-Sound)试验为在意大利、瑞士、西班牙和智利开展的前瞻性非劣效3期随机临床试验。
  • 2012年2月6日至2017年6月30日共入组1463例任何年龄、肿瘤≤2 cm且术前腋窝超声阴性的乳腺癌女性,1:1随机接受前哨淋巴结活检或不做腋窝手术。
  • 意向治疗分析纳入1405例,其中前哨淋巴结活检组708例、不做腋窝手术组697例;数据分析时间为2022年10月10日至2023年1月13日。

主要发现

  • 意向治疗分析1405例患者的中位(IQR)年龄为60(52-68)岁,总体中位(IQR)肿瘤大小为1.1(0.8-1.5)cm,1234例(87.8%)为雌激素受体阳性且ERBB2(原HER2或HER2/neu)非过表达乳腺癌。
  • 前哨淋巴结活检组97例(13.7%)腋窝淋巴结阳性。
  • 前哨淋巴结活检组与不做腋窝手术组的疾病评估中位(IQR)随访分别为5.7(5.0-6.8)年与5.7(5.0-6.6)年。
  • 5年远处无病生存率前哨淋巴结活检组为97.7%,不做腋窝手术组为98.0%(log-rank P=.67;HR 0.84;90%CI 0.45-1.54;非劣效P=.02)。
  • 前哨淋巴结活检组观察到12例(1.7%)局部区域复发、13例(1.8%)远处转移和21例(3.0%)死亡;不做腋窝手术组观察到11例(1.6%)局部区域复发、14例(2.0%)远处转移和18例(2.6%)死亡。

关键数值与推荐

  • 主要终点为意向治疗分析的5年远处无病生存率:前哨淋巴结活检组97.7% vs 不做腋窝手术组98.0%(log-rank P=.67;HR 0.84;90%CI 0.45-1.54;非劣效P=.02)。
  • 次要终点包括远处复发累积发生率、腋窝复发累积发生率、无病生存、总生存和辅助治疗推荐。

临床怎么用

  • 作者认为,对于肿瘤≤2 cm且腋窝超声阴性、且缺乏病理信息不影响术后治疗计划的乳腺癌患者,可安全免除任何腋窝手术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes is not performed with curative intent. OBJECTIVE: To determine whether the omission of axillary surgery is noninferior to SLNB in patients with small BC and a negative result on preoperative axillary lymph node ultrasonography. DESIGN, SETTING, AND PARTICIPANTS: The SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound) trial was a prospective noninferiority phase 3 randomized clinical trial conducted in Italy, Switzerland, Spain, and Chile. A total of 1463 women of any age with BC up to 2 cm and a negative preoperative axillary ultrasonography result were enrolled and randomized between February 6, 2012, and June 30, 2017. Of those, 1405 were included in the intention-to-treat analysis. Data were analyzed from October 10, 2022, to January 13, 2023. INTERVENTION: Eligible patients were randomized on a 1:1 ratio to receive SLNB (SLNB group) or no axillary surgery (no axillary surgery group). MAIN OUTCOMES AND MEASURES: The primary end point of the study was distant disease-free survival (DDFS) at 5 years, analyzed as intention to treat. Secondary end points were the cumulative incidence of distant recurrences, the cumulative incidence of axillary recurrences, DFS, overall survival (OS), and the adjuvant treatment recommendations. RESULTS: Among 1405 women (median [IQR] age, 60 [52-68] years) included in the intention-to-treat analysis, 708 were randomized to the SLNB group, and 697 were randomized to the no axillary surgery group. Overall, the median (IQR) tumor size was 1.1 (0.8-1.5) cm, and 1234 patients (87.8%) had estrogen receptor-positive ERBB2 (formerly HER2 or HER2/neu), nonoverexpressing BC. In the SLNB group, 97 patients (13.7%) had positive axillary nodes. The median (IQR) follow-up for disease assessment was 5.7 (5.0-6.8) years in the SLNB group and 5.7 (5.0-6.6) years in the no axillary surgery group. Five-year distant DDFS was 97.7% in the SLNB group and 98.0% in the no axillary surgery group (log-rank P = .67; hazard ratio, 0.84; 90% CI, 0.45-1.54; noninferiority P = .02). A total of 12 (1.7%) locoregional relapses, 13 (1.8%) distant metastases, and 21 (3.0%) deaths were observed in the SLNB group, and 11 (1.6%) locoregional relapses, 14 (2.0%) distant metastases, and 18 (2.6%) deaths were observed in the no axillary surgery group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, omission of axillary surgery was noninferior to SLNB in patients with small BC and a negative result on ultrasonography of the axillary lymph nodes. These results suggest that patients with these features can be safely spared any axillary surgery whenever the lack of pathological information does not affect the postoperative treatment plan. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02167490.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Gentilini OD, Botteri E, Sangalli C, et al. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37733364. doi:10.1001/jamaoncol.2023.3759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。